Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Prediction: Visa Stock Hits $500 in 2028

The stock has been a standout in 2026, up 20% year to date.

Visa (V) has been steadily growing its revenue by a compound rate of approximately 20% since January 2026, and it is now trading near all-time highs. The global payments processing giant reported a 15% increase in total net revenue for fiscal year 2026, with adjusted earnings per share growing by 16% to $13.27. Cross-border transactions continue to drive growth, accounting for 13% of total payments volume growth in 2026, compared to 9% overall.

Visa generated over $22 billion in free cash flow this fiscal year and has reduced its share count by 20% in the past decade, leading to higher earnings per share and share prices. Management has also consistently raised the dividend each year. Analysts estimate that Visa will earn $15.03 per share in fiscal year 2027 and $17.14 per share in fiscal year 2028, resulting in 13% to 14% earnings growth for the next two years.

The stock currently trades at a valuation of just under 32 times earnings, which is considered reasonable given the company's growth rate. If Visa only meets analyst estimates and maintains its current stock valuation, shares could reach around $540 by the end of 2028, offering a 7% upside from the current price. While there are no guarantees on Wall Street, Visa's strong performance and consistent growth make it a compelling long-term investment.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fool.com →

More in Finance & Markets

The 1973 Oil Crisis Still Matters Today

Author Philip Delves Broughton is on Bloomberg This Weekend to discuss his new book, Embargo, and how the 1973 oil crisis transformed Saudi Arabia’s economic and political power while exposing the…

One Hand-Typed Number Made My Drug Valuation 4.5x Too High

My drug valuation desk said a Phase 2 cancer drug was worth $1.29 billion. After two small fixes, the same drug with the same sales forecast was worth $283.5 million. Neither bug crashed anything. The screen looked great the whole time. That is the kind of bug this post is about. The setup The desk is called Somota.

  • Somota tool miscalculated drug valuation
  • Success rate typed manually, incorrect
  • 30% success rate led to $283.5M valuation

More from Sunday 15 November →